May 22, 2014 — AbbVie, Inc., is facing a rapidly growing number of lawsuits from men who were injured by AndroGel (testosterone gel). The most recent claims involve heart attacks, stroke, and wrongful death.
One of the most recent lawsuit (PDF) was filed on behalf of Richard Bodwell Ott, a 58 year-old man from Delaware who died of a heart attack after taking AndroGel and Axiron. He used AndroGel from October 2011 to January 2012, and then Axiron until his death in April 2012.
CBS Denver has also reported on two men who are planning to file AndroGel lawsuits, including 51 year-old Edward Downes of Pennsylvania. He blames AndroGel for causing his stroke and says it “ruined his life.”
Another lawsuit will soon be filed on behalf of 59 year-old Stephen Nichols of Fort Collins, Colorado. He started taking AndroGel to treat fatigue and symptoms of low testosterone. Two years later, he had a heart attack. He says he continued using AndroGel until viewing an ad on TV from a law firm warning that AndroGel was associated with heart attacks. After contacting his doctor, he stopped using AndroGel and decided to file a lawsuit.
These stories are just a few in an onslaught of lawsuits involving testosterone therapy, most of which have been filed against AbbVie. On May 29, a panel of federal judges is set to decide whether to consolidate the litigation into a Multi-District Litigation (MDL), which is similar to a class action. Plaintiffs’ attorneys argue that this is necessary to prevent conflicting rulings in different courts, avoid duplicative discovery, and improve efficiency.